TWi Biotechnology begins Phase 2 trial for AC-203 in epidermolysis bullosa patients

pharmanewsdaily- October 21, 2018 0

TWi Biotechnology, a Taiwanese biopharmaceutical company, has initiated the enrollment of patients in a pivotal Phase 2 clinical trial evaluating its investigational drug, AC-203, for ... Read More

GNI Group to halt enrolment in Phase 2 liver fibrosis trial following positive results

pharmanewsdaily- October 2, 2018 0

Japanese biotech company GNI Group has announced it will cease enrolment of new patients in its Phase 2 liver fibrosis trial for the drug candidate ... Read More